The European Commission has officially authorized Rasonque (daraxonrasib) for the treatment of adults with metastatic pancreatic adenocarcinoma who have previously received at least one systemic therapy.
This decision, announced by Revolution Medicines on Monday marks a significant shift for a patient population that has long faced limited therapeutic alternatives beyond standard cytotoxic chemotherapy.
The approval covers all European Union member states, along with Iceland, Liechtenstein, and Norway.
The medication is a once-daily oral tablet designed as a RAS(ON) multi-selective, noncovalent, tri-complex inhibitor. Unlike some targeted therapies restricted to specific genetic profiles, the EC authorization permits use in patients regardless of whether they have an identified RAS tumor mutation.
For clinicians, this arrival offers a long-awaited option in a notoriously difficult-to-treat disease.
“For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy, underscoring the urgent need for new therapeutic approaches.”
said Thomas Seufferlein, medical director of the Clinic for Internal Medicine I at Ulm University Hospital.
The regulatory path was expedited through the European Medicines Agency’s Cancer Medicines Pathfinder project, a mechanism reserved for therapies addressing high unmet medical needs. This decision was heavily influenced by data from the global Phase III RASolute 302 registrational trial, which compared a 300mg daily dose of Rasonque monotherapy against four different investigator-chosen chemotherapy regimens. The study met its primary and key secondary endpoints across the intent-to-treat group.
While the approval is a milestone, the reality of patient access remains a fragmented process.
Revolution Medicines CEO Mark Goldsmith said that the company is currently working with healthcare systems across the region to handle national pricing, health-technology assessments, and reimbursement procedures. Because these frameworks are handled at the national level, the timeline for when an individual patient might receive the drug will vary significantly by country.
The clinical profile of the drug also requires careful management by care teams. During the trial, dermatologic and soft tissue toxicities were common, affecting 86% of patients, with 10% experiencing grade 3 toxicity. These manifestations include rash, pruritus, paronychia, dry skin, and skin fissures. Physicians will need to follow established protocols for dose reduction or temporary interruption to manage these side effects effectively.
| Trial Parameter | Details |
|---|---|
| Study Name | RASolute 302 (NCT06625320) |
| Drug Dosage | 300mg daily (monotherapy) |
| Primary Comparison | Investigator’s choice of cytotoxic chemotherapy |
| Dermatologic Toxicity (All Grades) | 86% |
| Grade 3 Dermatologic Toxicity | 10% |
The scope of this authorization does not include Switzerland or the UK, as both maintain independent regulatory frameworks separate from the European Commission. Meanwhile, Revolution Medicines is continuing to expand its footprint in the oncology space. The company is currently evaluating Rasonque in other late-stage trials for metastatic RAS-mutant non-small cell lung cancer and is building out its commercial infrastructure following an earlier, separate approval from the US Food and Drug Administration.
Beyond the immediate clinical rollout, the industry is watching how this drug fits into broader oncology portfolios. In August, Revolution Medicines finalized a multi-part collaboration with BeOne Medicines to further develop targeted oncology therapies, showing an aggressive push to move beyond current limitations in RAS-targeted treatment.
More on Rasonque
The European Commission has approved daraxonrasib (RASONQUE®), the first broad RAS-targeted therapy for metastatic pancreatic cancer An important milestone for patients with pancreatic adenocarcinoma 💜 A promising step forward!#PancreaticCancer@RevMedicines
🚨Breaking🚨 European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancerhttps://t.co/UURiEo0LcP Learn more 👉 https://t.co/XtygaGCht0#LARVOL #CancerResearch #CancerData #Oncology… pic.twitter.com/myo4n47XcY
Daraxonrasib (Rasonque), an oral RAS inhibitor from Revolution Medicines, is now approved in Europe for previously treated metastatic pancreatic cancer, regardless of RAS mutation status. The phase 3 RASolute 302 trial showed improved survival compared with chemotherapy.…
$RVMD European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer More Info: https://t.co/iFDYlKNirR pic.twitter.com/ZsVf9upDEt